Turning Point Therapeutics

Turning Point Therapeutics is a clinical-stage precision oncology company with a portfolio of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting ROS1 and TRK oncogenic drivers for non-small cell lung cancer and advanced solid tumors. Turning Point’s next-generation kinase inhibitors are designed to bind more precisely and with greater affinity to their targets than current therapies, and their novel, compact structure has demonstrated the ability to overcome treatment resistance common with other kinase inhibitors. The company is committed to developing therapies that represent a turning point in cancer care for patients.